Open access peer-reviewed Edited Volume

Multiple Myeloma

Ota Fuchs

Institute of Hematology and Blood Transfusion

Ota Fuchs obtained his Ph.D. in Biochemistry from the Charles University, Czech Republic. He has undertaken, as a visiting scientist, short-term affiliations in the Beatson Institute for Cancer Research, Glasgow, UK; Institute of Experimental Medicine of the Russian Academy of Medical Sciences in St Peterburg, Russia; and in the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada.

Covering

Trisomies and Translocations Myc translocations Phosphoinositide 3-kinase NF-kappaB Bortezomib Carfilzomib Thalidomide Lenalidomide Daratumumab Elotuzumab or Emplicity Upfront Induction Treatment Conditioning Regimen

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Multiple myeloma (MM)is a plasma cell malignancy characterized by neoplastic proliferation of clonal plasma cells producing a monoclonal immunoglobulin. Nuclear factor-kappaB (NF-κB) stimulates the transcription of proteins that promote cell survival, growth and reduce susceptibility to apoptosis. This signalling pathway is constitutively activated in MM. Two distinct Wnt pathways (Wnt/β-catenin and Wnt/RhoA) are aberrantly activated in MM. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway is also over induced in MM. Therefore, inhibitors of these signalling pathways are used in the treatment of MM. Autologous stem cell transplantation has been a foremost improvement in MM therapeutics. It is considered the standard of care for all medically fit, newly diagnosed MM patients. Over the past decade, newly introduced therapeutic regimens, mainly proteasome inhibitors and immunomodulatory drugs, have significantly improved treatment outcome and survival of MM.

However, most of these patients relapse, underlining the need for new therapeutic approaches. Immunotherapies using new specific CD38 and CD319 antibodies, Daratumumab and Elotuzumab or Empliciti, checkpoint inhibitors and chimeric antigen receptor-modified T (CAR T) cells therapies will improve the treatment of MM patients. The most recent innovative immunologic approach has been CAR T cells, which have demonstrated the ability to selectively kill cancer cells and also overcome all conventional drug-related resistance mechanisms. Proteolysis targeting chimeric molecule (PROTAC) ARV825 caused ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation downregulates Myc expression contributing to MM cells growth inhibition. All these items will be discussed in this book.

Publishing process

Book initiated and editor appointed

Date completed: August 31st 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: September 28th 2020

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: November 27th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: February 15th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: April 16th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Ota Fuchs

Institute of Hematology and Blood Transfusion

Ota Fuchs graduated from the Chemical Technological University, Prague, Czech Republic in 1971. He obtained his PhD in Biochemistry from the Faculty of Natural Sciences, Charles University, Prague in 1981. He is currently employed as a Senior Scientist at the Institute of Hematology and Blood Transfusion, Prague. He has undertaken, as a visiting scientist, short-term affiliations in the Beatson Institute for Cancer Research, Glasgow, UK; Institute of Experimental Medicine of the Russian Academy of Medical Sciences in St Peterburg, Russia; and in the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada. He was principal investigator of five projects for the Internal Grant Agency of Ministry of Health of Czech Republic and of one grant project for the Grant Agency of Czech Republic.

View profile

Book chapters authored 5

Books edited 3

Introducing your Author Service Manager

Ms. Maja Bozicevic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire